Skip to main content
Digital Seminar

MDMA-Assisted Therapy in the Treatment of Posttraumatic Stress Disorder

$69.99 Standard

In the first ever phase 3 trial of MDMA for Posttraumatic Stress Disorder (PTSD), it was reported that 67% of the group who received MDMA, compared to 32% of the group who received placebo, no longer qualified for a PTSD diagnosis after three MDMA treatment sessions. Now, a second Phase 3 clinical trial is nearing completion with a possibility of MDMA becoming an available treatment in the near future. The aim of this recording is to prepare clinicians with an understanding of MDMA-assisted psychotherapy for PTSD in light of this eventuality.

Here's What You'll Learn


  • What is MDMA-assisted therapy? 
  • How is it used for PTSD? 
  • Theorized mechanisms of action 
  • How to discuss MDMA in your practice today 
     

Everything You're Getting


  • More than 1 hour of video content
  • Up to 1.0 CE credits
  • Certificate of completion
  • Handouts and resources

Meet Your Experts


Ingmar Gorman, PhD

Toggle speaker biography

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist and supervisor on the same study. He is co-author on a Nature Medicine paper reporting the results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Dr. Gorman has also published on the topics of classic psychedelics, ketamine, and Psychedelic Harm Reduction and Integration.
 

Speaker Disclosures:
Financial: Dr. Ingmar Gorman is the co-founder and CEO of Fluence International Inc., the lead scientific advisor for Journey Clinical, and receives grants from Beckley Psytech . He receives royalties as a published author. Dr. Gorman receives a speaking honorarium from Psychotherapy Networker and PESI, Inc.
Non-financial: Dr. Ingmar Gorman has no relevant non-financial relationships.

100% Satisfaction Guarantee

Register for this intensive training course without risk. If you're not completely satisfied, give us a call at 800-844-8260.

We’re that confident you'll find this learning experience to be all that's promised and more than you expected.

PESI App


Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world's best instructors, and complete your CE requirements anywhere, anytime, at your own pace.


Access for Self-Study (Non-Interactive)

Access never expires for this product.

Questions?

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info

Want this training for your whole team?

Get a customized training package for your team at a discounted rate!


Media Type:
Digital Seminar
Product Code:
NOS096247
Duration:
1 hour, 4 minutes
Copyright:
Jul 27, 2022
Closed Captions:
Available
Format:
Audio and Video

ADA Needs


We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.

Some text some message..
Back to Top